Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27941582 | 0.93 | RAD52 (0.33) | RAD52KLKB1F11USP1PTGDR2 | |
| SCHEMBL2916645 | 0.84 | HCRTR1 (0.33) | KMT2A | |
| SCHEMBL2921514 | 0.82 | HTR2C (0.32) | — | |
| SCHEMBL2943200 | 0.82 | CNR2 (0.32) | RAD52CNR2 | |
| SCHEMBL2923517 | 0.81 | F11 (0.33) | KLKB1F11MEN1NPC1GAA | |
| SCHEMBL2912950 | 0.81 | RXRA (0.35) | F11MEN1NPC1GAARAB9A | |
| SCHEMBL2921842 | 0.81 | F11 (0.33) | KLKB1F11MEN1NPC1GAA | |
| SCHEMBL2946662 | 0.81 | CNR2 (0.32) | RAD52CNR2 | |
| SCHEMBL2921640 | 0.81 | BRD4 (0.32) | — | |
| SCHEMBL2916848 | 0.80 | PDE4A (0.32) | F11MEN1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664811-B | (1H-1,2,4-triazol-1-yl) aryl compound and preparation method thereof | IHARA CHEMICAL IND CO. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-103664811-A | Aryl (1h-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL IND CO | 2014-03-26 | — | — | CN | disclosed |
| US-8648207-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8440838-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2226317-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | CYP1A1, CYP2S1, NAT1 | RAD52 4546/4885KLKB1 4586/4885F11 383/4885 |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | CYP1B1, CYP1A1, AOC3 | RAD52 4356/4885KLKB1 3663/4885F11 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.